Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation.

Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Aberg V, Walker JN, Seed PC, Almqvist F, Chapman MR, Hultgren SJ.

Nat Chem Biol. 2009 Dec;5(12):913-9. doi: 10.1038/nchembio.242. Epub 2009 Oct 25.

2.

The UbiI (VisC) Aerobic Ubiquinone Synthase Is Required for Expression of Type 1 Pili, Biofilm Formation, and Pathogenesis in Uropathogenic Escherichia coli.

Floyd KA, Mitchell CA, Eberly AR, Colling SJ, Zhang EW, DePas W, Chapman MR, Conover M, Rogers BR, Hultgren SJ, Hadjifrangiskou M.

J Bacteriol. 2016 Sep 9;198(19):2662-72. doi: 10.1128/JB.00030-16. Print 2016 Oct 1.

3.

Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.

Guiton PS, Cusumano CK, Kline KA, Dodson KW, Han Z, Janetka JW, Henderson JP, Caparon MG, Hultgren SJ.

Antimicrob Agents Chemother. 2012 Sep;56(9):4738-45. doi: 10.1128/AAC.00447-12. Epub 2012 Jun 25.

4.

Modulation of curli assembly and pellicle biofilm formation by chemical and protein chaperones.

Andersson EK, Bengtsson C, Evans ML, Chorell E, Sellstedt M, Lindgren AE, Hufnagel DA, Bhattacharya M, Tessier PM, Wittung-Stafshede P, Almqvist F, Chapman MR.

Chem Biol. 2013 Oct 24;20(10):1245-54. doi: 10.1016/j.chembiol.2013.07.017. Epub 2013 Sep 12.

5.

Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors.

Hadjifrangiskou M, Gu AP, Pinkner JS, Kostakioti M, Zhang EW, Greene SE, Hultgren SJ.

J Bacteriol. 2012 Nov;194(22):6195-205. doi: 10.1128/JB.01012-12. Epub 2012 Sep 14.

6.

Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract.

Ulett GC, Valle J, Beloin C, Sherlock O, Ghigo JM, Schembri MA.

Infect Immun. 2007 Jul;75(7):3233-44. Epub 2007 Apr 9.

7.
8.

Curli fimbria: an Escherichia coli adhesin associated with human cystitis.

Cordeiro MA, Werle CH, Milanez GP, Yano T.

Braz J Microbiol. 2016 Apr-Jun;47(2):414-6. doi: 10.1016/j.bjm.2016.01.024. Epub 2016 Mar 2.

9.

Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria.

Pinkner JS, Remaut H, Buelens F, Miller E, Aberg V, Pemberton N, Hedenström M, Larsson A, Seed P, Waksman G, Hultgren SJ, Almqvist F.

Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17897-902. Epub 2006 Nov 10.

10.

Community behavior and amyloid-associated phenotypes among a panel of uropathogenic E. coli.

Lim JY, Pinkner JS, Cegelski L.

Biochem Biophys Res Commun. 2014 Jan 10;443(2):345-50. doi: 10.1016/j.bbrc.2013.11.026. Epub 2013 Nov 15.

11.

Design and synthesis of fluorescent pilicides and curlicides: bioactive tools to study bacterial virulence mechanisms.

Chorell E, Pinkner JS, Bengtsson C, Edvinsson S, Cusumano CK, Rosenbaum E, Johansson LB, Hultgren SJ, Almqvist F.

Chemistry. 2012 Apr 10;18(15):4522-32. doi: 10.1002/chem.201103936. Epub 2012 Mar 16.

12.

Suppression of type 1 pilus assembly in uropathogenic Escherichia coli by chemical inhibition of subunit polymerization.

Lo AW, Van de Water K, Gane PJ, Chan AW, Steadman D, Stevens K, Selwood DL, Waksman G, Remaut H.

J Antimicrob Chemother. 2014 Apr;69(4):1017-26. doi: 10.1093/jac/dkt467. Epub 2013 Dec 8.

13.

Bacterial amyloid formation: structural insights into curli biogensis.

Van Gerven N, Klein RD, Hultgren SJ, Remaut H.

Trends Microbiol. 2015 Nov;23(11):693-706. doi: 10.1016/j.tim.2015.07.010. Epub 2015 Oct 1. Review.

14.

In Vivo Consumption of Cranberry Exerts ex Vivo Antiadhesive Activity against FimH-Dominated Uropathogenic Escherichia coli: A Combined in Vivo, ex Vivo, and in Vitro Study of an Extract from Vaccinium macrocarpon.

Rafsanjany N, Senker J, Brandt S, Dobrindt U, Hensel A.

J Agric Food Chem. 2015 Oct 14;63(40):8804-18. doi: 10.1021/acs.jafc.5b03030. Epub 2015 Sep 29.

PMID:
26330108
15.

Virulence and Fitness Determinants of Uropathogenic Escherichia coli.

Subashchandrabose S, Mobley HL.

Microbiol Spectr. 2015 Aug;3(4). doi: 10.1128/microbiolspec.UTI-0015-2012. Review.

16.

'Omic' Approaches to Study Uropathogenic Escherichia coli Virulence.

Lo AW, Moriel DG, Phan MD, Schulz BL, Kidd TJ, Beatson SA, Schembri MA.

Trends Microbiol. 2017 Sep;25(9):729-740. doi: 10.1016/j.tim.2017.04.006. Epub 2017 May 24. Review.

PMID:
28550944
17.

Biogenesis and adhesion of type 1 and P pili.

Lillington J, Geibel S, Waksman G.

Biochim Biophys Acta. 2014 Sep;1840(9):2783-93. doi: 10.1016/j.bbagen.2014.04.021. Epub 2014 May 2. Review.

PMID:
24797039
18.

Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli.

Greene SE, Pinkner JS, Chorell E, Dodson KW, Shaffer CL, Conover MS, Livny J, Hadjifrangiskou M, Almqvist F, Hultgren SJ.

MBio. 2014 Oct 28;5(6):e02038. doi: 10.1128/mBio.02038-14.

19.

Adhesive fiber stratification in uropathogenic Escherichia coli biofilms unveils oxygen-mediated control of type 1 pili.

Floyd KA, Moore JL, Eberly AR, Good JA, Shaffer CL, Zaver H, Almqvist F, Skaar EP, Caprioli RM, Hadjifrangiskou M.

PLoS Pathog. 2015 Mar 4;11(3):e1004697. doi: 10.1371/journal.ppat.1004697. eCollection 2015 Mar.

20.

Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37.

Kai-Larsen Y, Lüthje P, Chromek M, Peters V, Wang X, Holm A, Kádas L, Hedlund KO, Johansson J, Chapman MR, Jacobson SH, Römling U, Agerberth B, Brauner A.

PLoS Pathog. 2010 Jul 22;6(7):e1001010. doi: 10.1371/journal.ppat.1001010.

Supplemental Content

Support Center